KR100441158B1 - The functional drinks containing Crataegi fructus extracts and process for preparation thereof - Google Patents
The functional drinks containing Crataegi fructus extracts and process for preparation thereof Download PDFInfo
- Publication number
- KR100441158B1 KR100441158B1 KR10-2002-0017827A KR20020017827A KR100441158B1 KR 100441158 B1 KR100441158 B1 KR 100441158B1 KR 20020017827 A KR20020017827 A KR 20020017827A KR 100441158 B1 KR100441158 B1 KR 100441158B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- activity
- hawthorn
- weight
- present
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title description 7
- 238000002360 preparation method Methods 0.000 title description 5
- 230000000694 effects Effects 0.000 claims abstract description 25
- 241000282374 Puma concolor Species 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000020510 functional beverage Nutrition 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 9
- 230000002087 whitening effect Effects 0.000 claims abstract description 9
- 206010020772 Hypertension Diseases 0.000 claims abstract description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 22
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 239000000469 ethanolic extract Substances 0.000 abstract description 7
- 230000001766 physiological effect Effects 0.000 abstract description 6
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- 235000020717 hawthorn extract Nutrition 0.000 description 23
- 238000002835 absorbance Methods 0.000 description 16
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 14
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 14
- 102000003425 Tyrosinase Human genes 0.000 description 14
- 108060008724 Tyrosinase Proteins 0.000 description 14
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 12
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000012488 sample solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229940079877 pyrogallol Drugs 0.000 description 5
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 4
- 241000657480 Crataegus pinnatifida Species 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229940074360 caffeic acid Drugs 0.000 description 3
- 235000004883 caffeic acid Nutrition 0.000 description 3
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 241000123854 Crataegus pinnatifida var. major Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000003639 vasoconstrictive effect Effects 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 244000068485 Convallaria majalis Species 0.000 description 1
- 235000009046 Convallaria majalis Nutrition 0.000 description 1
- 244000160089 Crataegus cuneata Species 0.000 description 1
- 244000265913 Crataegus laevigata Species 0.000 description 1
- 241001019578 Crataegus maximowiczii Species 0.000 description 1
- 235000000344 Crataegus maximowiczii Nutrition 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 235000000836 Epigaea repens Nutrition 0.000 description 1
- 241000759268 Frangula betulifolia Species 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000008375 Hymenaea courbaril Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 241000369592 Platycephalus richardsoni Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 235000013202 a hawthorn Nutrition 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 superoxide radicals Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- ZIIBNXKQZAUBRD-UHFFFAOYSA-N vitexin 4'-o-α-l-rhamnopyranoside Chemical compound OC1C(O)C(O)C(C)OC1OC1=CC=C(C=2OC3=C(C4C(C(O)C(O)C(CO)O4)O)C(O)=CC(O)=C3C(=O)C=2)C=C1 ZIIBNXKQZAUBRD-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/02—Antioxidant
Abstract
본 발명은 산사자 추출물을 함유한 기능성 음료 및 그 제조방법에 관한 것으로, 산사자의 열수추출물 또는 에탄올추출물을 농축하여 분말형태로 제조한 다음 그것의 생리활성을 조사한 결과 항산화 활성이 높고 미백효과가 있으며 안지오텐신 전환 효소의 저해활성 뛰어났다. 따라서, 본 발명 산사자 추출물을 함유한 기능성 음료는 상기의 항산화 활성이 높고 미백효과가 있으며 고혈압을 예방하는 데 뛰어난 효과가 있다.The present invention relates to a functional beverage containing a mountain lion extract and a method for preparing the same, which are prepared in a powder form by concentrating the hot water extract or ethanol extract of the mountain lion, and then examined its physiological activity and has high antioxidant activity, whitening effect, and angiotensin The inhibitory activity of the converting enzyme was excellent. Therefore, the functional beverage containing the sansa extract of the present invention has a high antioxidant activity, a whitening effect, and has an excellent effect of preventing hypertension.
Description
본 발명은 산사자 추출물을 함유한 기능성 음료 및 그 제조방법에 관한 것으로, 더욱 상세하게는 본 발명은 항산화 활성이 높고 미백효과가 있으며 고혈압 예방에 효과가 있는 산사자 추출물을 함유한 기능성 음료의 제조에 관한 것이다.The present invention relates to a functional beverage containing a mountain lion extract and a method for preparing the same, and more particularly, the present invention relates to the production of a functional beverage containing a mountain lion extract having high antioxidant activity, whitening effect and effective in preventing hypertension. will be.
산사자(山査子,Crataegi fructus)는 산리홍 및 우리나라 각지의 산야와 계곡에서 자생하는 산사나무(Crataegus pinnatifida,BUNGE)의 열매로써 장미과(Rosaceae)에 속하며 다소 특이한 향긋한 냄새와 단맛 및 신맛을 갖고 있다. 아가위나무라고도 하는 낙엽, 활엽의 작은 교목으로서 키는 6m 정도 자라고 가지에 뾰족한 가시가 있다. 5∼6월에 직경 약 1.5∼1.8 cm의 흰 꽃을 피우며, 아가위라고도 부르는 산사열매는 공처럼 생긴 핵과(核果)로 9∼10월에 붉게 익으며, 작은 사과와 같은 구형으로 직경이 1.5∼2.5 cm이며 탄백색의 작은 점이 산재해 있다. 일반적으로 화채로 만들어 먹거나 날것으로 먹으며, 술로 빚어 마시기도 한다. 햇볕에 말린 열매를 산사자(山査子Crataegi Fructus)라고 하여 한방에서는 치습제·평사제로 사용하며, 고기를 먹은 후에 소화제로 먹기도 한다. 주산지는 중국의 변영성의 남부 주변에 많고 모래와 돌이 많은 건조한 산의 여면에서 많이 볼 수 있으며, 일본에서는 공원이나 정원의 분재로서 많이 재배되고 있고 외국에서는 메이플라워라고도 한다.Mountain Lion ( Crataegi fructus ) is a fruit of Sanryong and Crataegus pinnatifida ( BUNGE) , which grows in wild fields and valleys in Korea. It is a deciduous and deciduous arbor tree, also known as a locust tree, grows about 6m in height and has sharp thorns on its branches. White flowers of about 1.5-1.8 cm in diameter bloom in May-June. The hawthorn, also called agawi, is a ball-like nucleus and ripens in September-October, and is a small apple-like sphere with a diameter of 1.5- 2.5 cm, scattered with small white spots. In general, it is made of colorful or eaten raw, and is often drunk. Sun-dried fruit is called Sansa ( Crataegi Fructus ) and is used as a moisturizer and medicinal herb in oriental medicine. It is also eaten as a digestive agent after eating meat. Jusanji is found in many dry, sandy and stony dry mountainsides around the southern part of China's transfiguration. In Japan, it is cultivated as a bonsai in parks and gardens, and is also called mayflower in foreign countries.
우리나라에서는 털산사나무, 아광나무(Crataegus maximowiczii), 자작잎산사나무(C. pinnatifida f. betulifolia), 넓은잎산사나무(C. pinnatifida var. major), 가새잎산사나무(C. pinnatifida var. partita), 좁은잎산사나무(C. pinnatifida var. psilosa) 및 산사나무(C. pinnatifid var. typica) 등 7종의 산사나무들이 야생하거나 혹은 자생하고 있다. 이들 식물의 성숙한 과실을 채취하여 건조시킨 다음, 생약에서는 산사자(Crataegi Fructus)라 하여 중국원산인 북산사(C. pinnatifida var. major의 과실), 남산사(C. cuneata의 과실)와 함께 건위, 소화, 정장약 등으로 많이 사용하고 있다. 유럽에서도 찔광이나무(C. oxyacantha)등의 과실이 약용되고 있다.In Korea, the hawthorn, Crataegus maximowiczii , birch ( C. pinnatifida f. Betulifolia ), broadleaf hawthorn ( C. pinnatifida var. Major ), and brash hawthorn ( C. pinnatifida var. Partita 7 kinds of wild hawthorn, wild jasminoides , C. pinnatifida var. Psilosa and C. pinnatifid var. Typica . After harvesting and drying the mature fruits of these plants, they are called hawthorn ( Crataegi Fructus ) in Chinese herbal medicine ( Buksansa (fruit of C. pinnatifida var. Major ) native to China, Namsansa (fruit of C. cuneata ) Digestion, formal medicine, etc. are used a lot. Fruits such as C. oxyacantha are also used in Europe.
중국의 경우, 산사자는 생약, 한방약으로서 이용되었지만 또한 사탕과자나 약선요리 재료로서 그리고 젤리 등 사람들의 생활에 밀착된 식품으로서 사용되고 있다.In China, mountain lions are used as herbal medicines and herbal medicines, but they are also used as candy and medicinal ingredients, and as foods closely related to people's lives such as jelly.
산사의 약성과 약능을 보면, 성(性)은 미온무독(微溫無毒), 맛은 감산(甘酸)하며, 귀경(歸經)은 비(脾), 위(胃), 간경(肝經)이며, 특히 산사육(山査肉)은 소식적(消食積), 요산건위(療疝健胃), 치육적(治肉積), 산어혈(疝瘀血), 구조충(驅條蟲)하며 징가, 담음, 비만, 탄산, 사리, 장풍, 산후아침통, 오로부진, 소아유식정체, 월경통, 요통 등의 치료에 사용된다고 하였다. 특히 건위, 소화, 수렴, 진통, 살균, 살충에 좋은 효능이 알려지고 있으며, 숙취에도 좋다고 전해오고 있다. 이에 반해 유럽산 산사는 잎과 꽃의 추출물은 순화기 질환인 고혈압, 협심증, 부정맥, 관상동맥 경화증, 고 콜레스테롤 혈증 등의 치료에 사용되고 있다.Sansa's weakness and medicinal properties are lukewarm, non-toxic and subtractive in taste, while the ear is secreted in the stomach, stomach and liver. In particular, mountain breeding (山査 肉) is news (소식 食 積), uric acid health (위 健胃), toothy (治 肉 積), mountain fish blood (疝 瘀血), structural insects (驅 條 蟲) It is said to be used for the treatment of jinga, soak, obesity, carbonic acid, saree, jangfeng, postpartum morning pain, obesity, pediatric stagnation, dysmenorrhea and low back pain. In particular, good health, digestion, astringent, analgesic, sterilization, insecticides are known to be good, and is said to be good for hangovers. In contrast, European Sansa leaves and flowers extracts are used for the treatment of circulatory diseases such as hypertension, angina, arrhythmia, coronary atherosclerosis and hypercholesterolemia.
산사자의 약리성분에는 우르솔산(ursolic acid), 쿠엘세틴(quercetin), 크라태골산(crataegolic acid), 타타르산(tartaric acid), 하이퍼사이드 바이텍신-4-람노사이드(hyperoside vitexin-4-rhamnoside), 시트르산(citric acid), 카페산(caffeic acid), 콜린(choline), 아스코르브산(ascorbic acid, 0.089%), 탄수화물(22%), 단백질(0.7%), 지방(0.2%), 리파아제 등이 함유되어 있다.Pharmacological components of mountain lions include ursolic acid, quercetin, crataegolic acid, tartaric acid, and hyperside vitexin-4-rhamnoside. Citric acid, caffeic acid, choline, ascorbic acid (0.089%), carbohydrate (22%), protein (0.7%), fat (0.2%), lipase, etc. It is contained.
최근에는 천연물의 생리활성에 관한 연구가 활발히 진행되고 있다. 김 등은 생약재인 산사추출물의 항산화성을 탐색한 결과, 항산화 효과는 합성 항산화제보다 우수함을 밝혔고, 천연물로부터 분리된 항산화 성분인 페놀계 화합물은 이들이 갖는 수산기가 유리 산화물 중 유리기 수용체로서 산패의 초기단계에 안정된 공명체(resonance hybrid)를 형성하므로 산화억제작용을 하는 것으로 알려져 있다. 산사의 페놀성 성분은 산사의 유리형 페놀산에서 카페산, 프로토카테츄산(protocatechuic acid) 및 파이로갈롤(pyrogallol), 용성 에스테르형 페놀산에서 카페산, 플로로글루시놀(phloroglucinol), 불용성 페놀산에서 프로토카테츄산 및 프롤로글루시놀이 밝혀지면서 산사추출물의 주된 항산화성 물질임을 확인하였다.Recently, research on the physiological activity of natural products has been actively conducted. Kim et al. Found that the antioxidative effect of medicinal herb extracts was superior to synthetic antioxidants.Phenol-based compounds, which are antioxidant components isolated from natural products, have hydroxyl groups as free radical acceptors among free oxides. Since it forms a stable hybrid in a step (resonance hybrid) is known to act as an antioxidant. The phenolic constituents of the acidic acid are caffeic acid, protocatechuic acid and pyrogallol in the free phenolic acid of the acidic acid, caffeic acid in the soluble ester type phenolic acid, phloroglucinol, insoluble phenols. Protocatechuic acid and prologlucinol were identified in the acid, confirming that they are the main antioxidants of the hawthorn extract.
현재 산사에 대한 대부분의 임상학적 연구나 약리학적 연구 및 그것의 약효성분에 대한 연구는 많이 진행되어 있으나 한국산 산사자의 효소학적인 측면의 생리활성 기능에 대한 연구는 큰 진척을 보지 못하고 있고, 또한 음료로 상품화 개발은 아직까지 이루어지지 않고 있다.Currently, most clinical studies, pharmacological studies, and medicinal components of the midwifery have been conducted. However, studies on the enzymatic aspects of physiological activity of Korean midwifery have not progressed much. The development of commercialization has not been done so far.
따라서, 본 발명의 목적은 생약재로서 많이 사용되는 한국산 산사자의 생리활성 기능을 검증하고 산사자 추출물을 함유한 기능성 음료 및 그 제조방법을 제공함에 있다.Accordingly, an object of the present invention is to verify the physiological activity of Korean hawthorn, which is widely used as a herbal medicine, and to provide a functional drink containing hawthorn extract and a method of manufacturing the same.
본 발명의 상기 목적은 한국산 산사자를 열수추출 및 에탄올추출하여 동결건조시킨 후 분말상태로 얻은 다음 전자공여능 및 슈퍼옥사이드 디스뮤테이즈의 활성을 측정하여 항산화 활성을 조사하고 티로시네이즈 저해활성을 측정하여 미백효능을 조사하고 또한 안지오텐신 전환 효소의 저해활성을 조사하여 고혈압 예방효과를 조사한 다음 상기에서 얻은 산사자 추출물에 산사자 향, 꿀, 비타민C, 구연산, 과당을 첨가하여 산사자추출물을 함유한 기능성 음료를 제조함으로써 달성하였다.The above object of the present invention is obtained by lyophilization by hot water extraction and ethanol extraction of Korean hawthorn, and then obtained in a powder state to investigate the antioxidant activity by measuring the electron donating ability and superoxide dismutase activity by measuring the tyrosinase inhibitory activity The anti-hypertensive effect was investigated by investigating the whitening effect and the inhibitory activity of angiotensin converting enzyme, and then preparing the functional beverage containing the hawthorn extract by adding hawthorn fragrance, honey, vitamin C, citric acid and fructose to the hawthorn extract obtained above. By achieving this.
도 1은 본 발명의 산사자 추출물의 전자공여능을 분석하는 과정을 도식화한 것이다.Figure 1 is a schematic of the process of analyzing the electron donating ability of the hawthorn extract of the present invention.
도 2는 본 발명의 산사자 추출물의 전자공여능을 조사한 결과를 그래프로 나타낸 것이다.2 is a graph showing the results of the electron donating ability of the hawthorn extract of the present invention.
도 3은 본 발명의 산사자 추출물의 슈퍼옥사이드 디스뮤테이즈(SOD)의 유사활성을 측정하는 과정을 도식화한 것이다.Figure 3 illustrates the process of measuring the similar activity of the superoxide dismutase (SOD) of the mountain lion extract of the present invention.
도 4는 본 발명의 산사자 추출물의 슈퍼옥사이드 디스뮤테이즈(SOD)의 유사활성을 측정한 결과를 그래프로 나타낸 것이다.Figure 4 shows the result of measuring the similar activity of the superoxide dismutase (SOD) of the mountain lion extract of the present invention.
도 5는 본 발명의 산사자 추출물의 티로시네이즈 저해활성을 측정하는 과정을 도식화한 것이다.Figure 5 is a schematic of the process for measuring the tyrosinase inhibitory activity of the hawthorn extract of the present invention.
도 6은 본 발명의 산사자 추출물의 티로시네이즈 저해활성을 측정한 결과를 그래프로 나타낸 것이다.Figure 6 shows the result of measuring the tyrosinase inhibitory activity of the mountain lion extract of the present invention.
도 7은 본 발명의 산사자 추출물의 안지오텐신 전환 효소(ACE)저해활성을 측정하는 과정을 도식화한 것이다.Figure 7 illustrates the process of measuring the angiotensin converting enzyme (ACE) inhibitory activity of the hawthorn extract of the present invention.
도 8은 본 발명의 산사자 추출물의 안지오텐신 전환 효소(ACE)저해활성을 측정한 결과를 그래프로 나타낸 것이다.8 is a graph showing the results of measuring the angiotensin converting enzyme (ACE) inhibitory activity of the hawthorn extract of the present invention.
본 발명은 한국산 산사자에 증류수를 가하여 열수추출물 및 에탄올추출물을 얻는 단계; 상기 추출물을 동결건조하여 농축하여 분말화하는 단계; 산사자 추출물의 전자공여능 및 슈퍼옥사이드 디스뮤테이즈 활성, 티로시네이즈 저해활성 및 안지오텐신 전환 효소의 저해활성을 조사하는 단계; 상기 산사자 추출물에 산사자 향, 꿀, 비타민C, 구연산, 과당을 첨가하여 음료를 제조하는 단계로 구성된다.The present invention comprises the steps of adding hot water extract and ethanol extract by adding distilled water to the Korean mountain lion; Lyophilizing the extract to concentrate and powder; Investigating the electron donating ability and superoxide dismutase activity, tyrosinase inhibitory activity and inhibitory activity of angiotensin converting enzyme of the hawthorn extract; Comprising the production of a beverage by adding the hawthorn fragrance, honey, vitamin C, citric acid, fructose to the hawthorn extract.
이하, 본 발명의 구체적인 구성 및 작용을 실시예를 들어 설명하지만, 본 발명의 권리범위가 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the specific configuration and operation of the present invention will be described with reference to Examples, but the scope of the present invention is not limited only to these Examples.
[실시예]EXAMPLE
실시예 1 : 산사자 추출물의 제조Example 1 Preparation of Hawthorn Extract
산사자 추출물의 제조Preparation of Hawthorn Extract
본 발명에 사용된 산사자(Crataegi Fructus)는 대구 약령시장에서 한국산 산자자를 구입하여 물로 세척하여 음건 후 사용하였으며 시료의 추출은 시료 100g에 증류수 10배의 양을 가하여 80℃에서 3시간 환류냉각 추출하여 상등액과 침전물을 분리하여 상등액은 별도로 모아두고 침전물을 위와 같은 방법으로 1회 반복 추출하였으며. 시료의 에탄올 추출은 시료 100g에 70% 에탄올 10배의 양을 가하여 실온에서 24시간 추출하여 상등액과 침천물을 분리하여 위와 같은 방법으로 1회 반복 추출하였다. 각각 추출 분리된 상등액은 원심분리 및 여과, 농축하여 동결건조 후 냉동실에 보관하며 본 발명의 시료로 사용하였다.The mountain lion ( Crataegi Fructus ) used in the present invention was purchased after washing Korean water from Daegu Yangnyeong Market and dried in the shade. The extraction of the sample was performed by reflux extraction at 80 ° C. for 3 hours by adding 10 times the amount of distilled water to 100 g of the sample. The supernatant and sediment were separated, the supernatant was collected separately, and the precipitate was extracted once and repeatedly. Ethanol extraction of the sample was added to the 100g sample 10 times the amount of 70% ethanol and extracted for 24 hours at room temperature to separate the supernatant and sediments were extracted once again in the same manner as above. Each extracted supernatant was centrifuged, filtered, concentrated, lyophilized, stored in a freezer, and used as a sample of the present invention.
시약 및 기기Reagents and Instruments
산사자의 생리활성을 측정하기위한 효소실험에 사용된 시약은 DPPH(시그마사 제품), 크산틴(시그마사제품), XOase(시그마사 제품), 파이로갈롤(시그마사 제품), L-Dopa(시그마사 제품), 티로시네이즈(tyrosinase, 시그마사 제품), 래빗 렁 아세톤 분말(Rabbit lung acetone powder, 시그마사 제품), HHL(시그마사 제품)등을 사용하였다.Reagents used in enzyme experiments to measure the physiological activity of hawthorn are DPPH (Sigma), Xanthine (Sigma), XOase (Sigma), Pyrogallol (Sigma), L-Dopa ( Sigma company), tyrosinase (Sigma company), rabbit lung acetone powder (Rigbit lung acetone powder, Sigma company), HHL (Sigma company) and the like were used.
산사자 추출물이 흑색종 세포(Melanoma cell)의 증식에 미치는 영향을 조사한 실험에 사용된 MTT assay는 RPMI 1640 배지(기브코사 제품)과 소태반혈청(Fetal bovine serum, 시그마사 제품), 페니실린/스트렙토마이신(기브코사 제품), MTT(시그마사 제품), 트립신 250(디프코사 제품)을 사용하였으며, 트립판 블루 스테인 0.4%(Trypan blue stain 0.4%, 기브코사 제품)와 헤마사이토미터(haemacytometer, 마리엔필드사 제품)를 사용하였다. 그 외 기타 시약은 특급 시약을 사용하였다.The MTT assay used in experiments to investigate the effects of hawthorn extracts on the proliferation of melanoma cells was performed using RPMI 1640 medium (Gibcosa), fetal bovine serum (Sigma), penicillin / streptomycin (Gibco Co., Ltd.), MTT (Sigma Co., Ltd.), Trypsin 250 (Diffco Co., Ltd.) was used, Trypan blue stain 0.4% (Trypan blue stain 0.4%, Gibco Co., Ltd.) and hemasytometer (haemacytometer, Marien) Field company) was used. Other reagents were used as express reagents.
본 발명에 사용된 기기로는 UV/vis 분광광도계(히타치사 제품), 회전형 진공 증발기(rotary vacuum evaporator, 도쿄리카키카이사 제품), 원심분리기(히타치사 제품), 동결건조기(일신사 제품), 광학현미경(올림푸스사 제품), CO2배양기(한백 사이언티픽사 제품), pH미터(오리온 리서치사 제품), B.O.D 배양기(한백사 제품), 가압증기멸균기(한백 사이언티픽사 제품), ELISA 리더(바이오래드사 제품) 등을 사용하여 측정하였다.Instruments used in the present invention include UV / vis spectrophotometer (Hitachi Co., Ltd.), rotary vacuum evaporator (Tokyo Rikakikai Co., Ltd.), centrifuge (Hitachi Co., Ltd.), lyophilizer , Optical microscope (Olympus), CO 2 incubator (Hanbaek Scientific), pH meter (Orion Research), BOD incubator (Hanbaek Scientific), pressurized steam sterilizer (Hanbaek Scientific), ELISA reader It measured using (Biorad Corporation make).
실시예 2 : 산사자 추출물의 생리활성 측정Example 2: Determination of the biological activity of the hawthorn extract
실험예 1 : 산사자 추출물의 전자공여능 측정Experimental Example 1 Measurement of Electron Donating Ability of Sansa Extract
유리 라디칼은 미토콘드리아, 식세포 또는 세포질 중의 크산틴 옥시데이즈나 글루타티온 리덕타아제와 같은 플라보엔자임(flavoenzyme)에 의한 대사과정 중에서 생물학적 반응으로 발생하며, 전자공여작용은 이러한 산화성 유리 라디칼에 전자를 제공하여 산화를 억제하게 된다. 따라서, 산사자 추출물의 산화 억제 정도를 측정하기 위해 전자공여능을 조사하였다. 산사자 추출물의 전자공여능(electron donating abilities, EDA)은 Blois의 방법을 변형하여 도 1에 따라 측정하였다. 각 시료용액 2.0mL 2×10-4M의 α,α-디페닐-β-피크릴-하이드라질(DPPH) 1.0mL 넣고 교반한 후 30분간 방치한 다음 517nm에서 흡광도를 측정하였다. 전자공여능은 시료용액의 첨가구와 무첨가구의 흡광도 감소율로 나타내었다.Free radicals occur as biological reactions during metabolism by flavoenzymes such as xanthine oxidase or glutathione reductase in the mitochondria, phagocytes or cytoplasm, and electron donating acts to provide electrons to these oxidative free radicals Inhibits oxidation. Therefore, the electron donating ability was investigated to determine the degree of antioxidant inhibition of the hawthorn extract. Electron donating abilities (EDA) of the hawthorn extracts were measured according to FIG. 1 by modifying the method of Blois. Each sample solution 2.0mL 2 × 10 -4 M of α, α- diphenyl picryl -β- - After stirring Hyde Brazilian (DPPH) into 1.0mL was allowed to stand for 30 min and then the absorbance was measured at 517nm. The electron donating ability was expressed as the absorbance reduction rate of the sample solution addition and no addition solution.
SAbs: 517nm에서 측정한 시료의 흡광도S Abs : absorbance of the sample measured at 517 nm
BAbs: 517nm에서 DPPH 대신 측정한 증류수의 흡광도B Abs : absorbance of distilled water measured at 517 nm instead of DPPH
CAbs: 517nm에서 시료 대신 측정한 증류수의 흡광도C Abs : absorbance of distilled water measured at 517 nm instead of sample
도 2에 나타난 바와 같이, 각 추출물에 대한 DPPH 라디칼 소거 활성을 측정한 결과, 추출물의 농도가 증가할수록 전자공여능은 증가하는 경향을 나타내었으며 산사자 100ppm 농도의 열수추출물 및 에탄올추출물은 29.5%와 35.7%의 전자공여능을 나타냈고 500ppm 농도에서는 각각 89.4%와 91.8%의 매우 높은 전자공여능을 나타내었다. 또한, 1,000ppm의 농도에서는 92%, 97.8%의 전자공여능을 나타냈다. 이는 합성 항산화제인 BHT가 100ppm, 500ppm 및 1,000ppm의 농도에서 각각 26.3%와 44.8%, 66.7%의 전자공여능을 나타낸 것과 비교하여 본 발명의 산사자 추출물이 높은 전자공여능을 갖는 것을 알 수 있었다.As shown in FIG. 2, as a result of measuring the DPPH radical scavenging activity of each extract, the electron donating ability was increased as the concentration of the extract increased, and the hot water extract and the ethanol extract of 100 ppm of hawthorn were 29.5% and 35.7%. The electron donating ability of showed high electron donating ability of 89.4% and 91.8% at 500ppm concentration, respectively. In addition, the concentration of 1,000 ppm showed electron donating ability of 92% and 97.8%. It was found that the hawthorn extract of the present invention has a high electron donating ability as compared to the synthetic antioxidant BHT showed an electron donating ability of 26.3%, 44.8%, 66.7% at the concentration of 100ppm, 500ppm and 1,000ppm, respectively.
실험예 2 : 슈퍼옥사이드 디스퓨테이즈(SOD)의 유사활성 측정Experimental Example 2: Measurement of the similar activity of the superoxide dissolves (SOD)
슈퍼옥사이드 디스퓨테이즈는 생체내에서 슈퍼옥사이드 라디칼을 산소로 산화시켜주는 천연 항산화제로 단백질 또는 효소의 일종으로 활성 산소종을 안정한 물질로 전환시켜 산소상해로부터 생체를 보호하는 기능으로 알려져 있다. 따라서 산화방지는 물론 노화억제와도 밀접한 관계가 있는 것으로 알려져 있는 SOD 유사활성을 산사자 추출물에서 측정하였으며 파이로갈롤(pyrogallol)의 자동산화 반응을 이용하여 조사하였다. SOD 유사활성은 Marklund의 방법에 따라 도 3의 방법으로 측정하였다. 각 시료용액 0.2mL에 Tris-HCl의 완충용액(50mM tris+10mM EDTA, pH 8.5)3.0mL와 7.2mM 파이로갈롤 0.2mL 가하여 25℃에서 10분간 반응시킨 후 1.0N HCl 0.1mL를 가하여 반응을 정지시키고 반응액 중 산화된 파이로갈롤의 양은 420nm에서 측정하였다. SOD의 유사활성은 시료용액의 첨가군와 무첨가군의 흡광도 감소율로 나타내었다.Superoxide dissolvease is a natural antioxidant that oxidizes superoxide radicals into oxygen in vivo. It is known as a protein or enzyme that converts active oxygen species into stable substances and protects living organisms from oxygen injury. Therefore, SOD-like activity, which is known to be closely related to anti-oxidation as well as anti-ageing, was measured in the extracts of the hawthorn and investigated by the automatic oxidation of pyrogallol. SOD-like activity was measured by the method of FIG. 3 according to Marklund's method. To 0.2 mL of each sample solution, 3.0 mL of Tris-HCl buffer solution (50 mM tris + 10 mM EDTA, pH 8.5) and 0.2 mL of 7.2 mM pyrogalol were added and reacted at 25 ° C. for 10 minutes, followed by reaction with 1.0 N HCl 0.1 mL. The amount of pyrogallol oxidized in the reaction solution was stopped and measured at 420 nm. The similar activity of SOD was shown by the absorbance reduction rate of the sample solution addition group and no addition group.
SAbs: 420nm 에서 측정한 시료의 흡광도S Abs : absorbance of the sample measured at 420 nm
BAbs: 420nm 에서 파이로갈롤 대신 측정한 완충액의 흡광도B Abs : absorbance of buffer measured at 420 nm instead of pyrogallol
CAbs: 420nm 에서 시료 대신 측정한 완충액의 흡광도C Abs : absorbance of buffer measured at 420 nm instead of sample
도 4에 나타난 바와 같이, 본 발명의 산사자의 각 추출물을 농도별로 SOD 유사활성을 조사한 결과 열수추출물 및 에탄올추출물은 5,000ppm에서 19.6%와 24.5%의 미미한 유사활성을 나타냈지만, 농도가 증가함에 따라 활성이 증가하였다.As shown in Figure 4, as a result of examining the SOD-like activity of each extract of the mountain lion of the present invention by concentration, the hot water extract and ethanol extract showed a slight similar activity of 19.6% and 24.5% at 5,000ppm, but as the concentration increased Activity increased.
실험예 3 : 산사자 추출물의 티로시네이즈 저해활성의 측정Experimental Example 3: Determination of Tyrosinase Inhibitory Activity of Sansa Extract
멜라닌은 동·식물과 미생물계에 널리 존재하는 고분자의 천연 색소로 생물체에 따라 다양한 종류가 알려져 있으며, 페놀류의 효소적, 비효소적 산화 및 중합반응등의 다단계 과정을 거쳐 생성된다. 티로시네이즈 저해활성에 대한 기작은 특히 화장품산업의 미백효과를 비롯한 식품산업의 갈변화 방지에 있어서 매우 중요한 부분이 될 수 있다.Melanin is a natural pigment of a polymer widely found in animals, plants and microorganisms. Various kinds of melanin are known according to organisms, and are produced through multi-step processes such as enzymatic and non-enzymatic oxidation and polymerization of phenols. The mechanism of tyrosinase inhibitory activity may be a very important part in the prevention of browning in the food industry, especially the whitening effect of the cosmetic industry.
생체내에서의 멜라닌 합성과정은 먼저 티로신을 기질로 하여 엘-3.4-디하이드록시페닐알라닌(L-3,4-dihydroxyphenylalanine)을 생성시키고 이를 다시 엘-도파퀴논(L-dopaquinone)으로 전이시키는 연속된 효소적 산화(하이드록실레이션과 산화)가 진행된 후 각 생성물의 중합반응 등에 의해 이루어진다.The in vivo melanin synthesis process is a continuous process of first producing L-3.4-dihydroxyphenylalanine using tyrosine as a substrate and transferring it back to L-dopaquinone. After enzymatic oxidation (hydroxylation and oxidation) proceeds by polymerization of each product.
三島 등은 멜라닌 생성 억제에 대한 접근을 크게 두 가지 타입으로 보고 있다. 그 중 하나는 멜라닌 생성의 주 효소인 티로시네이즈 효소자체를 직접 억제하는 타입이고 또 하나는 세포로부터 분리한 티로시네이즈에 대해서는 직접적인 억제를 나타내지 않지만 피부 색소세포내에 있어서의 멜라닌 생성을 억제하는 타입이다.Sanshima et al. See two major types of approaches to suppress melanogenesis. One type is a type that directly inhibits tyrosinase enzyme itself, which is a major enzyme of melanin production, and the other type is a type that suppresses melanin production in skin pigment cells, although there is no direct inhibition on tyrosinase isolated from cells. to be.
본 발명은 전자 타입에 대한 효소 활성의 저해효과를 본 것으로, 티로시네이즈의 저해활성 측정은 티로시네이즈의 작용 결과 생성되는 도파크롬(DOPA chrome)을 비색법에 의해 측정하는 Yagi등의 방법에 준하여 도 5의 방법에 따라 조사하였다. 기질로서 10mM L-DOPA 0.2mL, 0.175M 인산염 완충액(pH 6.8) 0.2mL 및 시료용액 0.5mL의 혼합액에 버섯의 티로시네이즈(110unit/mL) 0.1mL을 첨가하여 35℃에서2분간 반응시켜 반응액 중에 생성된 도파크롬을 475nm에서 측정하여 다음 식으로 저해율을 구하였다.The present invention is to see the inhibitory effect of the enzyme activity on the electronic type, the measurement of the inhibitory activity of tyrosinase according to the method of Yagi et al. To measure the dopa chrome produced by the action of tyrosinase by colorimetric method. It was investigated according to the method of FIG. To the mixture of 0.2 mL of 10 mM L-DOPA, 0.2 mL of 0.175 M phosphate buffer (pH 6.8) and 0.5 mL of sample solution, 0.1 mL of tyrosinase (110 units / mL) of mushroom was added and reacted at 35 ° C. for 2 minutes. Dopa chromium produced in the solution was measured at 475 nm, and the inhibition rate was calculated by the following equation.
SAbs: 475nm에서 측정한 시료의 흡광도S Abs : absorbance of the sample measured at 475 nm
BAbs: 475nm에서 효소 대신 측정한 완충액의 흡광도B Abs : absorbance of buffer measured at 475 nm instead of enzyme
CAbs: 475nm에서 시료 대신 측정한 완충액의 흡광도C Abs : absorbance of buffer measured at 475 nm instead of sample
도 6에 나타난 바와 같이, 버섯의 티로시네이즈를 사용하여 본 발명의 산사자의 각 추출물을 농도별로 티로시네이즈 활성의 저해효과를 측정한 결과, 산사자 열수추출물 및 에탄올추출물은 10,000ppm 이하의 농도에서는 저해효과를 나타내지 않았으나, 30,000ppm의 농도에서는 각각 49.8%, 62.4%의 높은 효소활성 저해를 나타냈다. 또한 50,000ppm에서는 각각 82.8%과 96.7%로 높은 저해활성을 나타내는 등 농도 의존적으로 효소 활성을 저해함을 알 수 있었다.As shown in Figure 6, by using the tyrosinase of mushrooms to measure the inhibitory effect of tyrosinase activity of each extract of the mountain lion of the present invention by concentration, the hot water extract and ethanol extract of the Although there was no inhibitory effect, high concentrations of 49.8% and 62.4% were inhibited at concentrations of 30,000 ppm, respectively. In addition, it was found that at 50,000 ppm, enzyme activity was inhibited in a concentration-dependent manner, showing high inhibitory activity at 82.8% and 96.7%, respectively.
실험예 4 : 안지오텐신 전환 효소(Angiotensin Converting Enzyme, ACE) 저해활성의 측정Experimental Example 4 Measurement of Inhibitory Activity of Angiotensin Converting Enzyme (ACE)
고혈압이 발생하는 메카니즘에서 레닌-안지오텐신 시스템(renin-angiotensin system)이 혈압조절에 매우 중요한 역할을 한다. 특히 안지오텐신 전환 효소는 레닌에 의하여 생성된 데카펩타이드(decapeptide)인 안지오텐신Ⅰ으로부터 C-말단의 이중펩타이드를 가수분해시킴으로서 강력한 혈관수축 작용을 갖는 옥타펩타이드(octapeptide)인 안지오텐신Ⅱ를 합성하는 마지막 단계에 관여하는 효소이다. 생성된 안지오텐신Ⅱ는 강력한 혈관수축작용을 가지며 부신피질에서 알도스테론(aldosterone)의 분비를 촉진함으로서 물과 소듐의 배설을 억제한다. ACE는 또한 혈관이완작용을 가진 노나펩타이드(nonapeptide)인 브라디키닌(bradykinin)을 불활성화 시킴으로서 결과적으로 혈압을 상승시키는 역할을 한다.In the mechanism of hypertension, the renin-angiotensin system plays an important role in blood pressure control. In particular, angiotensin converting enzyme is involved in the final step of synthesizing angiotensin II, an octapeptide having strong vasoconstrictive action by hydrolyzing C-terminal double peptide from angiotensin I, a decapeptide produced by renin. It is an enzyme. Angiotensin II produced has strong vasoconstrictive action and inhibits excretion of water and sodium by promoting the release of aldosterone from the adrenal cortex. ACE also inactivates bradykinin, a nonapeptide with vasorelaxant action, resulting in elevated blood pressure.
따라서, 본 발명의 산사자 추출물의 이러한 ACE의 저해활성을 측정하기위해 Cushman등의 방법을 변형하여 도 7의 방법에 따라 실시하였다. 즉, 실험군은 0.3M NaCl을 함유하는 0.1M 포타슘 인산염 완충액(pH 8.3)에 기질(Hippuryl-L-histidyl-L-leucine : HHL) 2.5mM을 녹인 액 0.15mL, 래빗 렁 아세톤 분말(Rabbit lung acetone powder) 0.1mL와 시료용액 0.1mL를 혼합했으며, 대조군은 시료용액 대신 증류수 0.1mL를 첨가하여 37℃에서 30분간 반응시키고 1N HCl 0.35mL 첨가로 반응을 중지시킨 뒤 3mL의 에틸아세테이트를 첨가하였다. 에틸아세테이트층으로부터 용매를 증류시킨 잔사에 1mL의 증류수를 첨가하여 추출된 히퓨르산(hippuric acid)을 흡광도 228㎚에서 측정하여 다음 식에 따라 저해율을 구하였다.Therefore, in order to measure the inhibitory activity of the ACE of the hawthorn extract of the present invention, a modification of Cushman et al. Was carried out according to the method of FIG. That is, the experimental group was dissolved 0.15mL of substrate (Hippuryl-L-histidyl-L-leucine: HHL) in 0.1M potassium phosphate buffer (pH 8.3) containing 0.3M NaCl, rabbit lung acetone powder (Rabbit lung acetone powder) 0.1mL and 0.1mL of the sample solution were mixed, and the control group was added 0.1mL of distilled water instead of the sample solution and reacted at 37 ° C for 30 minutes. The reaction was stopped by adding 0.35mL of 1N HCl, and then 3mL of ethyl acetate was added. 1 mL of distilled water was added to the residue from which the solvent was distilled from the ethyl acetate layer, and the extracted hyperfuric acid was measured at absorbance of 228 nm, and the inhibition rate was determined according to the following equation.
SAbs: 228nm에서 측정한 시료의 흡광도S Abs : absorbance of the sample measured at 228 nm
BAbs: 228nm에서 효소 대신 측정한 증류수의 흡광도B Abs : absorbance of distilled water measured at 228 nm instead of enzyme
CAbs: 228nm에서 시료 대신 측정한 증류수의 흡광도C Abs : absorbance of distilled water measured at 228 nm instead of sample
도 8에 나타난 바와 같이, 본 발명의 산사자 추출물의 ACE 효소 활성의 저해작용을 조사한 결과 산사자 추출물 10ppm의 농도에서 각각 32.7%와 34.5%의 저해활성이 나타냈으나, 농도가 증가함에도 저해활성에는 큰 변화가 없었고 에탄올 추출물보다 열수 추출물에서 ACE 저해활성이 높았다. 상기의 결과 산사자 추출물이 저농도에서 높은 활성을 보인 점은 주목할만한 결과이다.As shown in Figure 8, the inhibition of the ACE enzyme activity of the hawthorn extract of the present invention showed the inhibitory activity of 32.7% and 34.5% at a concentration of 10ppm hawthorn extract, respectively, but the inhibitory activity is great at increasing the concentration There was no change and ACE inhibitory activity was higher in hot water extract than ethanol extract. As a result, the hawthorn extract showed a high activity at a low concentration is a noteworthy result.
실시예 3 : 산사자 추출물을 함유한 기능성 음료의 제조Example 3 Preparation of Functional Drink Containing Sansa Extract
본 발명의 산사자 추출물은 상기 실시예 1의 제조방법에 따라 산사자 추출물을 얻고 실시예 2를 통하여 그것의 생리활성을 조사한 결과 항산화 활성이 높고 미백효과가 있으며 고혈압 예방효과가 높음을 확인하였다. 따라서, 상기의 효과를 갖는 산사자 추출물을 함유한 기능성 음료를 제조하기 위하여, 실시예 1의 방법에 따라 산사자 추출물을 얻고 상기 분말형태의 산사자 추출물 0.01∼10 중량% 에다 산사자 향 0.08중량%, 꿀 0.95중량%, 비타민C 0.1중량%, 구연산 0.1중량%, 과당 14중량%를 첨가하여 제조하였다.The mountain lion extract of the present invention obtained the mountain lion extract according to the preparation method of Example 1 and examined its physiological activity through Example 2 it was confirmed that the antioxidant activity is high, whitening effect and high blood pressure prevention effect. Thus, in order to prepare a functional beverage containing the mountain lion extract having the above effect, according to the method of Example 1 to obtain a mountain lion extract in the powder form of the lioness extract 0.01 ~ 10% by weight of the mountain lion flavor 0.08% by weight, honey 0.95 It was prepared by adding 0.1% by weight, 0.1% by weight of vitamin C, 0.1% by weight of citric acid, and 14% by weight of fructose.
이상과 같이 본 발명은 실시예를 통하여 설명한 바와 같이, 본 발명의 산사자의 열수추출물 및 에탄올추출물은 전자공여능이 높아 항산화 활성이 높고, 라디칼의 소거와 관련된 슈퍼옥사이드 디스뮤테이즈의 활성이 높으며, 미백효과가 있고, 안지오텐신 전환 효소의 활성을 저해하는 뛰어난 효과가 있다. 따라서, 본 발명의 산사자 추출물을 함유한 기능성 음료는 상기의 항산화 활성이 높고 미백효과가 있으며 고혈압을 예방하는데 뛰어난 효과가 있으므로 기능성 음료제조산업상 유용한 발명인 것이다.As described above, the present invention, as described through the examples, the hot water extract and ethanol extract of the mountain lion of the present invention has high electron donating ability, high antioxidant activity, high activity of superoxide dismutase related to scavenging of radicals, and whitening. It is effective and has an excellent effect of inhibiting the activity of angiotensin converting enzyme. Therefore, the functional beverage containing the hawthorn extract of the present invention is a useful invention in the functional beverage manufacturing industry because it has a high antioxidant activity, has a whitening effect, and has an excellent effect on preventing hypertension.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0017827A KR100441158B1 (en) | 2002-04-01 | 2002-04-01 | The functional drinks containing Crataegi fructus extracts and process for preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-0017827A KR100441158B1 (en) | 2002-04-01 | 2002-04-01 | The functional drinks containing Crataegi fructus extracts and process for preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030079064A KR20030079064A (en) | 2003-10-10 |
KR100441158B1 true KR100441158B1 (en) | 2004-07-21 |
Family
ID=32377449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0017827A KR100441158B1 (en) | 2002-04-01 | 2002-04-01 | The functional drinks containing Crataegi fructus extracts and process for preparation thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100441158B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271341A (en) * | 2013-05-23 | 2013-09-04 | 彭常安 | Processing method of health-care trchosahthes kirilowii maxin and hawthorn powder |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101384873B1 (en) * | 2011-09-20 | 2014-04-16 | 경희대학교 산학협력단 | Composition comprising extracts of Panax ginseng and Crataegis fructus for improving skin beauty |
KR101944082B1 (en) * | 2017-06-26 | 2019-01-31 | 제이앤팜유한책임회사 | Cosmetics for anti-aging or whitening of skin with ethanol extract of Crataegi fructus fruit and manufacturing method of producing the same |
KR102022067B1 (en) * | 2017-10-18 | 2019-09-18 | 한림성심대학교 산학협력단 | Cosmetics for anti-aging or whitening of skin with nanopaticle of water extract of Crataegi fructus fruit |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960000237A (en) * | 1994-06-13 | 1996-01-25 | 한동근 | Health food composition having a high blood pressure improving action |
JPH09266767A (en) * | 1996-03-29 | 1997-10-14 | Meiji Seika Kaisha Ltd | Food and drink containing extract of crataegus cuneata and used for improving endurance |
KR19990071101A (en) * | 1998-02-27 | 1999-09-15 | 서경배 | Diet drink composition |
JP2000139430A (en) * | 1998-11-04 | 2000-05-23 | Fuji Seiyaku:Kk | Fat reduced beverage and its production |
KR20000045576A (en) * | 1998-12-30 | 2000-07-25 | 유상옥 | Cosmetic composition containing the extract of crataegi fructus useful for removing free radicals from the skin |
JP2001145474A (en) * | 1999-11-18 | 2001-05-29 | Nikken Foods Co Ltd | Antioxidative and immune-improving beverage and method for producing the same |
KR100402421B1 (en) * | 2001-07-30 | 2003-10-17 | 화천군 | Manufacturing Method for Beverage Using Crataegue pinnatifida |
-
2002
- 2002-04-01 KR KR10-2002-0017827A patent/KR100441158B1/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960000237A (en) * | 1994-06-13 | 1996-01-25 | 한동근 | Health food composition having a high blood pressure improving action |
JPH09266767A (en) * | 1996-03-29 | 1997-10-14 | Meiji Seika Kaisha Ltd | Food and drink containing extract of crataegus cuneata and used for improving endurance |
KR19990071101A (en) * | 1998-02-27 | 1999-09-15 | 서경배 | Diet drink composition |
JP2000139430A (en) * | 1998-11-04 | 2000-05-23 | Fuji Seiyaku:Kk | Fat reduced beverage and its production |
KR20000045576A (en) * | 1998-12-30 | 2000-07-25 | 유상옥 | Cosmetic composition containing the extract of crataegi fructus useful for removing free radicals from the skin |
JP2001145474A (en) * | 1999-11-18 | 2001-05-29 | Nikken Foods Co Ltd | Antioxidative and immune-improving beverage and method for producing the same |
KR100402421B1 (en) * | 2001-07-30 | 2003-10-17 | 화천군 | Manufacturing Method for Beverage Using Crataegue pinnatifida |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271341A (en) * | 2013-05-23 | 2013-09-04 | 彭常安 | Processing method of health-care trchosahthes kirilowii maxin and hawthorn powder |
Also Published As
Publication number | Publication date |
---|---|
KR20030079064A (en) | 2003-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102317468B (en) | Proanthocyanidin of cashew apple, composition containing proanthocyanidin, and application thereof | |
KR20110054022A (en) | Skin-whitening agent, anti-aging agent, and skin-care cosmetic agent | |
KR101702138B1 (en) | Use of myrtle extract as depigmenting agent | |
KR20160021676A (en) | Cosmetic Compositions with Whitening and Anti-oxidative Effect Comprising of Phragmitis Rhizoma, Salicomia herbacea L. and Prunus mume | |
KR20170094903A (en) | Composition containing complex extracts including Veratrum nigrum var. ussuriense, Juglans mandshurica, Rodgersia podophylla and Chaenomeles sinensis with antioxidant activity or whitening | |
KR20170132388A (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR20150064314A (en) | Cosmetic Composition Comprising Mangifera indica L. Extract, Passiflora edulis Sims Extract, Hylocereus undatus (Haw.) Britt. and Rose Extract, Actinidia chinensis Planch. Extract and Annona Squamosa Extract | |
KR20150118078A (en) | Anti-wrinkle Cosmetic Composition Comprising Hylocereus undatus (Haw.) Britt. and Rose Extract | |
KR100760670B1 (en) | The manufacture method of nature pack composition having whitening effect | |
KR20190076620A (en) | Cosmetic composition having anti-depigmenting and whitening function and manufacturing method thereof | |
KR101819060B1 (en) | Cosmetic Compositions Containing Fermented Extracts of Hwangryunhaedoktang | |
KR20200127545A (en) | Composition of natural hair-dye | |
KR100441158B1 (en) | The functional drinks containing Crataegi fructus extracts and process for preparation thereof | |
KR20170048904A (en) | Cosmetic compositions for skin whitening containing costunolide from natural extracts | |
KR100755515B1 (en) | Functional drinks using Salicornia herbacea and a method of manufacturing process | |
KR101429117B1 (en) | Composition for skin-whitening comprising extract of calyx of peach blossom | |
KR102646545B1 (en) | Cosmetic composition for skin whitening or skin barrier improvement comprising Hosta longipes extract | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR102599579B1 (en) | Nanorization-treated fermented Hibiscus manihot with enhanced collagen, amino acid, polyphenol or flavonoid content and manufacturing method thereof | |
KR102149223B1 (en) | Cosmetic composition for skin whitening containing the fermented complex natural extracts | |
KR100883773B1 (en) | Cosmetic compositions comprising fermenting extracts of citrus junos fruit or poncirus trifoliata fruit with salt | |
KR102437871B1 (en) | Composition for preventing or improving of skin wrinkle or skin aging comprising roasted dried-radish-slices extracts, and healthy food comprising the composition | |
KR101147922B1 (en) | Cosmetic composition and skin beauty food | |
KR101190201B1 (en) | Cosmetic composition containing extract of pinus root | |
KR101764806B1 (en) | Method for manufacturing complex extract of Lycopodium clavatum and Equisetum arvense and cosmetic composition containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |